Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Anticipate generic drug launch
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Gastric retained gabapentin dosage form|
|Abstract:||A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.|
|Inventor(s):||Berner; Bret (El Granada, CA), Hou; Sui Yuen Eddie (Foster City, CA), Gusler; Gloria M. (Cupertino, CA)|
|Assignee:||Depomed, Inc. (Menlo Park, CA)|
1. A dosage form, comprising between about 100 mg to about 4800 mg of gabapentin or pharmaceutically acceptable salt thereof, dispersed in a single polymer matrix comprising
at least one swellable hydrophilic polymer that swells unrestrained dimensionally by imbibing water to increase its size to promote gastric retention of the dosage form in a stomach in a fed mode, wherein upon contact with water, gabapentin is released
by diffusion from the dosage form over a period of at least five hours and at least 40 wt % of the gabapentin is retained in the dosage form 1 hour after administration.
2. The dosage form of claim 1 wherein the dosage form swells to approximately 115% of its volume prior to administration within one hour after administration.
3. The dosage form of claim 1, wherein the dosage form swells to approximately 130% of its volume prior to administration at a time later than one hour after administration.
4. The dosage form of claim 1, comprising between about 200-4000 mg gabapentin.
5. The dosage form of claim 1, comprising between about 200-2700 mg gabapentin.
6. The dosage form of claim 1, comprising between about 300-3600 mg gabapentin.
7. The dosage form of claim 1, comprising between about 500-3600 mg gabapentin.
8. The dosage form of claim 1, comprising between about 900-3600mg gabapentin.
9. The dosage form of claim 1, comprising between about 900-2400 mg gabapentin.
10. The dosage form of claim 1, wherein the gabapentin has a bioavailability greater than or equal to 80% of an equal dose of gabapentin in an immediate release dosage form.
11. The dosage form of claim 1, wherein the polymer matrix is comprised of a polymer having a molecular weight of between about 4.times.10.sup.3 to 1.times.10.sup.7 Daltons.
12. The dosage form of claim 1, wherein the swellable hydrophilic polymer comprises poly(ethylene oxide).
13. The dosage form of claim 12 wherein the poly(ethylene oxide) has a viscosity average molecular weight of between 2.times.10.sup.6 and 7.times.10.sup.6 Daltons.
14. The dosage form of claim 1, wherein the swellable hydrophilic polymer comprises hydroxypropylmethylcellulose.
15. The dosage form of claim 14, wherein the hydroxypropylmethylcellulose has a molecular weight such that a 1% aqueous solution has a viscosity at room temperature of between about 4,000-10,0000 centipoise.
16. The dosage form of claim 1, wherein the polymer matrix comprises poly(ethylene oxide) and hydroxypropylmethylcellulose.
17. The dosage form of claim 16 further comprising a lubricating agent.
18. The dosage form of claim 17 wherein the lubricating agent is magnesium stearate.
19. The dosage form of claim 1, comprising about 600 mg gabapentin.
20. The dosage form of claim 1, comprising about 300 mg of gabapentin.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.